

1-800-533-1710

**ATHAL** 

Alpha-Globin Gene Analysis, Varies

Patient ID SA00140510			Birth Date 1969-09-09	Gender <b>F</b>	Age <b>51</b>	
Order Number SA00140510	Client Order Number SA00140510	Ordering Physician CLIENT,CLIENT	Report Notes			
Account Information C7028846 DLMP Rochest	er	Collected 23 Nov 2020 12:00	-			

MCR

## **Alpha-Globin Gene Analysis**

### Alpha-Globin Gene Analysis (ATHL)

Result Summary	MCR	Released By MCF
NEGATIVE		VICTORIA WAUGH
<b>Result</b> No deletions or duplications within the alpha globin gene cluster were identified. Neither the Hb Constant Spring r the alphaT Saudi alterations were identified.		An online research opportunity called GenomeConnect (genomeconnect.org), a project of ClinGen, is available for the recipient of this genetic test. This patient registry collects de- identified genetic and health information to advance the knowledge of genetic variants. Mayo Clinic is a collaborator of ClinGen. This may not be applicable for all tests.
Interpretation	MCR	Test results should be interpreted in the context of clinical
This result reduces the likelihood, but does not rule out a diagnosis of or positive carrier status for alpha thalassen		findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
This assay does not detect non-deletion types of mutations such as point mutations other than the alphaT Saudi and Constant Spring. Therefore, this result should be interpre- the context of clinical presentation and results of other la tests [e.g. hemoglobin electrophoresis and mean corpus	d Hb eted in aborat <mark>ory</mark>	Rare polymorphisms exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.
volume (MCV)]. A genetic consultation may be of benefit.		Bone Marrow transplants from allogenic donors will interfere with testing. Call Mayo Clinic Laboratories for instructions for testing patients who have received a bone marrow transplant.
Specimen	MCR	One or more in silico tools were used to assist in the
WB Whole Blood		interpretation of these results. These tools are updated regularly and predictions for a given variant may change. Additionally, the predictability of these tools for the determination of pathogenicity
Method	MCR	is currently unvalidated.
Dosage analysis (PCR and MLPA) was used to detect de and duplication-type mutations and the Hb Constant Sp alphaT Saudi point mutations within the alpha globin ger cluster(GenBank accession number NM_000517; build ( (hg19)). This method uses multiple probes that hybridize	ring and Te GRCh37	This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Received: 24 Nov 2020 14:55

Reported: 25 Nov 2020 08:29

#### **Performing Site Legend**

(3'HVR).

throughout the alpha-gene locus on chromosome 16 from the

HS-40 regulatory region through the 3' hypervariable region

Code	Laboratory	Address	Lab Director	<b>CLIA Certificate</b>
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



THEV0

1-800-533-1710

Thalassemia Summary Interpretation, Blood

Patient ID	Patient Name		Birth Date	Gender	Age
SA00140510	VALIDATIONTESTING, THEV1		1969-09-09	F	51
Order Number	Client Order Number	Ordering Physician	Report Notes		
SA00140510	SA00140510	CLIENT, CLIENT			
Account Information		Collected			
C7028846 DLMP Rochest	er	23 Nov 2020 12:00			

# **Thalassemia Summary Interpretation**

MCR

#### **MOLECULAR RESULTS:**

Alpha Globin Cluster Del/Dup: Negative

**Thalassemia Summary Interpretation** 

#### SUMMARY INTERPRETATION:

1) Alpha globin gene deletion/duplication testing is negative for the most common causes of alpha thalassemia (large deletional alpha globin mutations and two common non-deletional alpha thalassemia mutations, Hb Constant Spring and AlphaT Saudi). This greatly reduces the likelihood of, but does not entirely exclude, an alpha thalassemia mutation as this assay does not detect less common non-deletional alpha thalassemia mutations. Alpha globin gene sequencing is available if clinically indicated. If desired, please call the Metabolic Hematology Laboratory at 1– 800–533–1710.

2) Ferritin level is not supportive of iron deficiency. Correlation

with iron studies is recommended.

3) No evidence of hemoglobin variants or beta thalassemia was detected by protein analysis. The vast majority of hemoglobin variants and beta thalassemias are excluded, although some rare clinically significant hemoglobin disorders are electrophoretically silent. Beta globin gene sequencing and beta globin cluster locus deletion/duplication analysis are available if clinically indicated. If desired, please call the Metabolic Hematology Laboratory at 1–800–533–1710.

Genetic counseling may be of benefit to assist in the interpretation of these results.

**Reviewed By** 

JENNIFER MAIN

Received: 24 Nov 2020 14:53

Reported: 25 Nov 2020 09:37

MCR

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



Thalassemia and Hemoglobinopathy Evaluation, Blood and Serum

Patient ID	Patient Name		Birth Date	Gender	Age
SA00140510	VALIDATIONTESTING, THEV1		1969-09-09	F	51
Order Number	Client Order Number	Ordering Physician	Report Notes		
SA00140510	SA00140510	CLIENT, CLIENT			
Account Information		Collected			
C7028846 DLMP Rochest	er	23 Nov 2020 12:00			

## **Thalassemia and Hemoglobinopathy Ev**

#### **Hemoglobinopathy Interpretation**

1) No abnormal hemoglobin variant or beta thalassemia detected by protein methods.

2) The ferritin level is not supportive of iron deficiency. Correlation with iron studies is recommended.

3) Alpha thalassemia deletion/duplication testing (ATHAL) is pending. See THEV0/Thalassemia Summary Interpretation for correlation of these results with protein analysis and any provided clinical phenotype.

Methodologies utilized in this interpretation include: capillary electrophoresis, HPLC

#### **Reviewed By**

JENNIFER MAIN

#### Hb Variant, A2 and F Quantitation,B

Result Name	Value	Unit	Reference Value	Performing Site
Hb A	97.0	%	95.8–98.0	MCR
Hb F	0.5	%	0.0–0.9	MCR
Hb A2	2.5	%	2.0–3.3	1 MCR

Result Name	Value	Unit	Reference Value	Performing Site
HPLC Hb Variant, B	See Interpretation			MCR
Ferritin, S	50	mcg/L	11–307	MCR

Reported: 24 Nov 2020 15:14

# Received: 24 Nov 2020 14:53

#### Laboratory Notes

1 This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

#### **Performing Site Legend**

Code	Laboratory	Address	Lab Director	<b>CLIA Certificate</b>
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



MCR

THEV1